The hepatokine FGL1 regulates hepcidin and iron metabolism during anemia in mice by antagonizing BMP signaling

Ugo Sardo,Prunelle Perrier,Kevin Cormier,Manon Sotin,Jean Personnaz,Thanina Medjbeur,Aurore Desquesnes,Lisa Cannizzo,Marc Ruiz-Martinez,Julie Thevenin,Benjamin Billoré,Grace Jung,Elise Abboud,Carole Peyssonnaux,Elizabeta Nemeth,Yelena Z Ginzburg,Tomas Ganz,Léon Kautz
DOI: https://doi.org/10.1182/blood.2023022724
IF: 20.3
2024-01-18
Blood
Abstract:FGL1 regulates hepcidin expression during the recovery from anemia FGL1 is an antagonist of the BMP/SMAD signaling pathway As a functional component of erythrocyte hemoglobin, iron is essential for oxygen delivery to all tissues in the body. The liver-derived peptide hepcidin is the master regulator of iron homeostasis. During anemia, the erythroid hormone erythroferrone regulates hepcidin synthesis to ensure the adequate supply of iron to the bone marrow for red blood cells production. However, mounting evidence suggested that another factor may exert a similar function. We identified the hepatokine FGL1 as a previously undescribed suppressor of hepcidin that is induced in the liver in response to hypoxia during the recovery from anemia and in thalassemic mice. We demonstrated that FGL1 is a potent suppressor of hepcidin in vitro and in vivo. Deletion of Fgl1 in mice results in higher hepcidin levels at baseline and after bleeding. FGL1 exerts its activity by directly binding to BMP6, thereby inhibiting the canonical BMP-SMAD signaling cascade that controls hepcidin transcription.
hematology
What problem does this paper attempt to address?